Swipe Left For English News
1
承诺到2050年实现全价值链净零排放
2
符合SBTi最具雄心的1.5°C温室气体减排路径，展现出前瞻性与执行力
3
引领生物药绿色发展解决方案，技术创新赋能健康未来
上海,
2025年8月28日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布，其近期及净零温室气体减排目标已获科学碳目标倡议（Science Based Targets initiative，简称SBTi）认证。
药明生物是行业内首批获SBTi近期及净零减排目标认证的企业之一。SBTi是一家企业气候行动组织，通过推动企业和金融机构设定温室气体减排目标，助力全球相关机构在应对气候变化中贡献力量。
药明生物深知应对气候变化的重要性，为此制定了应对气候变化的综合战略、科学可量化的目标矩阵以及清晰路线图。公司于2021年设定温室气体减排密度目标，2022年设立运营净零排放目标，并在2025年推出了更具雄心的SBTi目标——这一目标矩阵涵盖范围1、范围2及范围3温室气体排放，并包含近期目标与净零目标，符合1.5°C温室气体减排路径。
在全力实现自身气候目标的同时，公司积极携手全球供应商伙伴，通过全面推动可持续供应链管理体系建设，驱动整个价值链迈向净零可持续未来。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们很开心公司的近期及净零温室气体目标已经顺利获得SBTi认证。这一认可将进一步激励我们坚定不移地应对气候变化，并引领行业向净零经济转型。作为全球生物药绿色解决方案领域的领军者，我们始终追求卓越的ESG表现，用端到端解决方案赋能全球合作伙伴，并与所有利益相关方携手推动整个价值链的负责任发展。
作为联合国全球契约组织（UNGC）和制药供应链倡议组织（PSCI）成员，药明生物积极倡导可持续发展的战略举措并赢得业界广泛认可。公司获得明晟（MSCI）最高AAA ESG评级、EcoVadis“铂金”评级、入选道琼斯可持续发展指数（DJSI）；荣登CDP水安全管理A级榜单和CDP“供应商参与度”A级榜单、获得CDP气候变化A-领导力评分；获评晨星Sustainalytics ESG“风险可忽略”最高评级以及“行业最高评级”与“区域最高评级”企业；入选富时社会责任指数系列；入选恒生ESG 50指数；ISS ESG评级“最佳”奖章认可，充分彰显了公司在可持续发展领域的卓越表现。
药明生物SBTi目标矩阵
净零目标
到2050年实现全价值链温室气体净零排放。
近期目标
以2024年为基准年，到2034年将范围1和范围2温室气体绝对排放量减少58.8%；同时，在相同期限内，将范围3“外购产品与服务”类别中对应每千克生物制品所产生的温室气体排放量减少63.8%。
长期目标
以2024年为基准年，到2050年将范围1和范围2温室气体绝对排放量减少90%；同时，在相同期限内，将范围3温室气体绝对排放量减少90%，包括外购产品和服务、固定资产、燃料和能源相关活动、上游运输和配送、运营过程中产生的废弃物和员工通勤类别。
关于 SBTi
科学碳目标倡议 (SBTi) 是一家企业气候行动组织，旨在帮助全球企业和金融机构在应对气候变化方面发挥应有作用。
该组织制定标准、工具和指南，使企业能够设定适当的温室气体减排目标，以便将全球变暖态势控制在灾难性水平以下，并最迟于2050年实现净零排放。
SBTi是一家慈善机构，旗下设有可提供目标验证服务的子公司。其合作伙伴包括CDP、联合国全球契约组织、全球商业气候联盟、世界资源研究所（WRI）和世界自然保护基金（WWF）。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产（CRDMO）公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福病患。
药明生物在中国、美国、爱尔兰、德国和新加坡拥有超过12000名员工。通过药明生物的专业服务团队，以及先进技术和精深洞见，公司为客户提供高效经济的生物药解决方案。截至2025年6月底，药明生物帮助客户研发和生产的综合项目高达864个，其中包括24个商业化生产项目。
药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。更多信息，请访问：www.wuxibiologics.com
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics' Near-Term and Net-Zero Targets Approved by SBTi
1
Committed to net-zero across the value chain by 2050
2
Aligned with 1.5°C mitigation pathways, the most ambitious SBTi designation
3
Leader in Green CRDMO to drive innovation for a healthier future
Shanghai,
August 28, 2025
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced its near-term and net-zero greenhouse gas (GHG) emissions reduction targets have been approved by the Science Based Targets initiative (SBTi).
WuXi Biologics is one of the first companies in the industry to receive approval for near-term and net-zero targets from SBTi, a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating climate change by setting goals to reduce greenhouse gas (GHG) emissions.
Deeply understanding the importance of tackling climate change, WuXi Biologics has adopted a broad, integrated strategy with measurable targets and a refined roadmap. The company set a GHG emission intensity reduction target in 2021, established an operational net-zero target in 2022, and introduced new, ambitious SBTi targets in 2025. Aligning with 1.5°C pathways to limit global warming, the SBTi target matrix covers Scope 1, 2, and 3 GHG emissions, and includes near-term and net-zero targets.
While diligently pursuing its own climate goals, WuXi Biologics also actively engages with its suppliers through comprehensive sustainable supply chain management to help achieve positive impacts across the entire value chain.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are delighted that our near-term and net-zero GHG targets have been approved by SBTi, an acknowledgement that further inspires our steadfast dedication to tackling climate change and leading the way to a net-zero economy. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to promote responsible practices.
As a participant of the United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP Water Security "A List" and Supplier Engagement Assessment "A List", and awarded a CDP Climate Change leadership-level "A-" score for two consecutive years; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
WuXi Biologics' SBTi Target Matrix
Overall Net-Zero Target
Reach net-zero greenhouse gas emissions across the value chain by 2050.
Near-Term Targets
Reduce absolute scope 1 and 2 GHG emissions 58.8% by 2034 from a 2024 base year; reduce scope 3 GHG emissions covering purchased goods and services 63.8% per kg of product produced within the same timeframe.
Long-Term Targets
Reduce absolute scope 1 and 2 GHG emissions 90% by 2050 from a 2024 base year; reduce absolute scope 3 GHG emissions covering purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, and employee commuting 90% within the same timeframe.
About SBTi
The Science Based Targets initiative (SBTi) is a corporate climate action organization that enables companies and financial institutions worldwide to play their part in combating the climate crisis.
It develops standards, tools and guidance which allow companies to set greenhouse gas(GHG) emissions reductions targets in line with what is needed to keep global heating below catastrophic levels and reach net-zero by 2050 at latest.
The SBTi is incorporated as a charity, with a subsidiary which will host its target validation services. Its partners are CDP, the United Nations Global Compact, the We Mean Business Coalition, the World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2025, WuXi Biologics is supporting 864 integrated client projects, including 24 in commercial manufacturing.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间收到药明生物最新消息
点击下方图片即刻报名
药明生物CRDMO⁺ Open Day
